Cipla concludes acquisition of generic businesses in US

18 Feb 2016 Evaluate

Cipla’s UK arm, Cipla (EU) has closed the transaction to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The acquisition was made by Cipla (EU) through a wholly owned special purpose vehicle which would merge into InvaGen Pharmaceuticals Inc. after the acquisition. The combined revenue for the two companies for the year-ended 2015 is over $230 million.

This acquisition is the second landmark acquisition in Cipla’s 80 year history - the first was Cipla Medpro, South Africa. This acquisition will give scale to Cipla’s US business - currently 8% of total revenue as well as providing a launch pad to introduce Cipla’s pipeline of products in respiratory and injectables, among others, in the coming years. Combined with the pipeline of InvaGen products, the overall portfolio will be wide-ranging and will cover chronic therapies like CVS, CNS, respiratory, oncology and diabetes among others.

The acquisition of InvaGen pharmaceuticals also provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved over the next 4 years. In addition, InvaGen has filed 5 first-to-file products. Dosage forms include immediate release, modified release and extended release tablets and capsules. With a manufacturing footprint of 350,000 square feet of GMP area, InvaGen has 3 units located in Long Island, NY, with a total production capacity of 12 billion tablets and capsules per annum and about 500 employees.


Cipla Share Price

1374.60 5.05 (0.37%)
22-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1374.60
Zydus Lifesciences 883.85
Lupin 2165.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×